AXL-specific single domain antibodies show diagnostic potential and antitumor activity in acute myeloid leukemia

被引：0
|
作者：
Vandewalle, Niels
Satilmis, Hatice
Verheye, Emma M.
Fan, Rong
Wang, Yanmeng
De Groof, Timo W.
Kerre, Tessa
De Beule, Nathan
De Becker, Ann
De Bruyne, Elke
Menu, Eline
Vanderkerken, Karin
Breckpot, Karine
Devoogdt, Nick
De Veirman, Kim
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-4181
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4181
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Expression profiling of some Acute Myeloid Leukemia - associated markers to assess their diagnostic/prognostic potential
    Mousa, Nahla O.
    Gado, Marwa
    Assem, Magda M.
    Dawood, Kamal M.
    Osman, Ahmed
    GENETICS AND MOLECULAR BIOLOGY, 2021, 44 (01) : 1 - 9
  • [22] Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target
    Park, Il-Kyoo
    Mishra, Anjali
    Chandler, Jason
    Whitman, Susan P.
    Marcucci, Guido
    Caligiuri, Michael A.
    BLOOD, 2013, 121 (11) : 2064 - 2073
  • [23] Activity of Carfilzomib (CFZ) in Acute Myeloid Leukemia (AML) As a Single Agent and in Novel Combinations
    Peng, Mao Yu
    Abaza, Yasmin
    Mcdermott, Martina
    Mead, Monica
    Slamon, Dennis J.
    Larson, Sarah
    BLOOD, 2020, 136
  • [24] Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia
    Leung, Wingchi K.
    Workineh, Aster
    Mukhi, Shivani
    Tzannou, Ifigeneia
    Brenner, Daniel
    Watanabe, Norihiro
    Leen, Ann M.
    Lulla, Premal
    BLOOD ADVANCES, 2020, 4 (02) : 387 - 397
  • [25] AMG 176 exhibits robust antitumor activity in combination with standard of care agents in models of acute myeloid leukemia
    Caenepeel, Sean
    Belmontes, Brian
    Osgood, Tao
    Cajulis, Elaina
    Coxon, Angela
    Canon, Jude
    Hughes, Paul E.
    CANCER RESEARCH, 2019, 79 (13)
  • [26] Selective inhibition of STAT5 expression in acute myeloid leukemia cells results in potent antitumor activity
    Zhou, Tianyuan
    Guo, Shuling
    Siwkowski, Andy
    Witchell, Donna
    Pandey, Sanjay
    Monia, Brett
    MacLeod, Robert
    Kim, Youngsoo
    CANCER RESEARCH, 2009, 69
  • [27] Antitumor activity of the potent and novel FLT3 inhibitor HM43239 in acute myeloid leukemia
    Lee, Miyoung
    Ha, Young Eun
    Moon, Mi Jin
    Byun, Joo-Yun
    Yu, HyunKyung
    Kang, SeokJong
    Lee, Jaeho
    Lee, Kyuhang
    Kim, Eunkyung
    Kim, Eunyoung
    Lee, Ho Jeong
    Kim, YoungHoon
    Ahn, YoungGil
    Suh, KweeHyun
    Kim, Sun-Jin
    CANCER RESEARCH, 2018, 78 (13)
  • [28] Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia
    Hellesoy, Monica
    Gullaksen, Stein-Erik
    Tislevoll, Benedicte Sjo
    Fagerholt, Oda Helen Eck
    Reikvam, Hakon
    Loges, Sonja
    Cortes, Jorge
    Heuser, Michael
    Chromik, Joerg
    Skavland, Jorn
    Sulen, Andre
    Bruserud, Oystein
    Lorens, Jim
    Gausdal, Gro
    Micklem, David
    Gjertsen, Bjorn T.
    BLOOD, 2016, 128 (22)
  • [29] Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324
    Hellesoy, Monica
    Wnuk-Lipinska, Katarzyna
    Boniecka, Anna
    Naevdal, Eline Milde
    Reikvam, Hakon
    Loges, Sonja
    Cortes, Jorge E.
    Skavland, Jorn
    Bruserud, Oystein
    Lorens, Jim
    Micklem, David
    Gausdal, Gro
    Gjertsen, Bjorn T.
    BLOOD, 2015, 126 (23)
  • [30] Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs
    Michael Fiegl
    Lars H. Lindner
    Matthias Juergens
    Hansjoerg Eibl
    Wolfgang Hiddemann
    Jan Braess
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 321 - 329
12345